123-I THYROID UPTAKE AT 24, 48, AND 72 HOURS FOLLOWING ADMINISTRATION OF RH-TSH

施用 RH-TSH 后 24、48 和 72 小时的 123-I 甲状腺摄取

• 批准号: 7379496
• 负责人: Lewis Braverman
• 金额: $ 0.27万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379496
• 关键词: 123; THYROID; UPTAKE; 24; 48

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recombinant human (rh-TSH) is routinely used in the monitoring if patients with thyroid cancer. Its administration stimulates thyroid radioiodine uptake (RAIU) and thyroglobulin release without the need to withdraw thyroid hormone therapy and render the patient hypothyroid. In this matter, a rh-TSH is FDA approved for the management of thyroid cancer and its safety in various subgroups, including euthyroid subjects and in those with nodular goiters, has been established. In normal euthyroid subjects and in patients with non-toxic multinodular goiters recombinant human TSH increases the radioiodine uptake (RAIU) at 24 hours. However, the precise duration of this increase in the RAIU from rh-TSH has not yet been described. The purpose of our study is to examine the effect of rh-TSH on the RAIU at 24, 48, and 72 hours after its administration. In addition, we will examine the duration and peak effect where the greatest increase on the RAIU is seen. Ultimately, this may facilitate post-operative management of thyroid cancer, as it will provide us with an optimal time frame at which to measure RAIU for improved visualization of thyroid metastases and residual thyroid bed tissue. We plan to recruit 15 subjects with normal thyroid glands and normal thyroid function. We will administer 0.1 mg of rh-TSH to all subjects and measure the 24-hour RAIU following the administration of 123-I at 24, 48, and 72 hours after rh-TSH administration. This information will also provide guidance for the optimal time after rh-TSH administration to give 131-I for the ablation if residual thyroid tissue after thyroidectomy for thyroid cancer and to decrease the size of large nodular non-toxic goiters.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。重组人（rh-TSH）常规用于监测甲状腺癌患者。它的管理刺激甲状腺放射性碘摄取（RAIU）和甲状腺球蛋白的释放，而不需要撤销甲状腺激素治疗，使患者甲状腺功能减退。在这个问题上，rh-TSH被FDA批准用于甲状腺癌的管理，并且已经确定了其在各种亚组中的安全性，包括甲状腺功能正常的受试者和结节性甲状腺肿的受试者。 在正常甲状腺功能正常的受试者和非毒性多结节性甲状腺肿患者中，重组人TSH增加了24小时的放射性碘摄取（RAIU）。然而，这种从rh-TSH的RAIU增加的精确持续时间尚未被描述。本研究的目的是检查rh-TSH在给药后24、48和72小时对RAIU的影响。此外，我们将研究持续时间和峰值效应，其中RAIU增加最大。最终，这可能有助于甲状腺癌的术后管理，因为它将为我们提供一个最佳的时间框架，以测量RAIU，改善甲状腺转移和残留甲状腺床组织的可视化。我们计划招募15名甲状腺正常且甲状腺功能正常的受试者。我们将对所有受试者给予0.1 mg rh-TSH，并在rh-TSH给药后24、48和72小时测量123-I给药后的24小时RAIU。该信息还将为rh-TSH给药后的最佳时间提供指导，以便在甲状腺癌甲状腺切除术后对残留甲状腺组织进行131-I消融，并减小大结节性无毒甲状腺肿的大小。